Jane Street’s Tonix Pharmaceuticals TNXP Stock Holding History

Jane Street’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$336K	Buy	24,400 +9,300	+62%	+$143K	﹤0.01%	8981
2025 Q4	$236K	Buy	+15,100	New	+$278K	﹤0.01%	9372

Other funds holding TNXP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JHC

Jones Hill Capital New York $466M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Jane Street's TNXP Position: Q1 2026 in Review

Jane Street sold out of Tonix Pharmaceuticals (TNXP) in Q1 2026, closing a stake of 30,626 shares — an estimated $471K sold.

Jane Street first reported a position in TNXP in Q2 2022 and held it in 8 quarters. The position peaked at $548K in Q4 2024. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

Jane Street reported no remaining Tonix Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Jane Street sold 30,626 Tonix Pharmaceuticals shares in Q1 2026, an estimated $471K.
Jane Street first reported a position in Tonix Pharmaceuticals in Q2 2022 and held it in 8 quarters.
Jane Street's Tonix Pharmaceuticals position peaked at $548K in Q4 2024.
81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.